Symbols / ARQT $23.75 +1.50% Arcutis Biotherapeutics, Inc.
ARQT Chart
About
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Fundamentals
Scroll to Statements| Market Cap | 2.97B | Enterprise Value | 2.84B | Income | -16.14M | Sales | 376.07M | Book/sh | 1.54 | Cash/sh | 1.78 |
| Dividend Yield | — | Payout | 0.00% | Employees | 354 | IPO | — | P/E | — | Forward P/E | 18.60 |
| PEG | — | P/S | 7.90 | P/B | 15.46 | P/C | — | EV/EBITDA | -375.57 | EV/Sales | 7.55 |
| Quick Ratio | 2.83 | Current Ratio | 3.17 | Debt/Eq | 60.44 | LT Debt/Eq | — | EPS (ttm) | -0.13 | EPS next Y | 1.28 |
| EPS Growth | — | Revenue Growth | 81.50% | Earnings | 2026-05-06 | ROA | -1.96% | ROE | -9.30% | ROIC | — |
| Gross Margin | 90.24% | Oper. Margin | 14.20% | Profit Margin | -4.29% | Shs Outstand | 125.07M | Shs Float | 91.91M | Short Float | 16.60% |
| Short Ratio | 12.10 | Short Interest | — | 52W High | 31.77 | 52W Low | 12.42 | Beta | 1.77 | Avg Volume | 1.28M |
| Volume | 805.73K | Target Price | $34.75 | Recom | Strong_buy | Prev Close | $23.40 | Price | $23.75 | Change | 1.50% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | main | Mizuho | Outperform → Outperform | $35 |
| 2026-02-27 | main | Guggenheim | Buy → Buy | $35 |
| 2026-02-26 | main | TD Cowen | Buy → Buy | $35 |
| 2026-02-26 | main | HC Wainwright & Co. | Buy → Buy | $34 |
| 2026-02-26 | main | Needham | Buy → Buy | $36 |
| 2026-01-26 | main | Needham | Buy → Buy | $31 |
| 2025-11-28 | main | Mizuho | Outperform → Outperform | $37 |
| 2025-10-30 | main | Goldman Sachs | Neutral → Neutral | $29 |
| 2025-10-28 | main | Needham | Buy → Buy | $30 |
| 2025-08-07 | main | Needham | Buy → Buy | $22 |
| 2025-07-25 | init | Goldman Sachs | — → Neutral | $18 |
| 2025-05-23 | reit | Needham | Buy → Buy | $20 |
| 2025-04-09 | reit | Needham | Buy → Buy | $20 |
| 2025-04-03 | reit | Guggenheim | Buy → Buy | — |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-04-03 | reit | Needham | Buy → Buy | $20 |
| 2025-03-11 | main | Jefferies | Buy → Buy | $19 |
| 2025-02-27 | main | Goldman Sachs | Neutral → Neutral | $15 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-02-26 | main | Mizuho | Outperform → Outperform | $21 |
- AAD backs steroid-free ZORYVE for children with eczema - Stock Titan Wed, 22 Apr 2026 12
- ARQT (Arcutis Biotherapeutics Inc.) tops Q4 2025 EPS estimates on 91 percent year over year revenue growth, shares slip 2.03 percent. - Crowd Risk Alerts - UBND thành phố Hải Phòng Wed, 22 Apr 2026 18
- Is Arcutis (ARQT) stock losing support (Slight Loss) 2026-04-20 - Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 16
- Does Positive Infant Atopic Dermatitis Data Alter The Bull Case For Arcutis Biotherapeutics’ ZORYVE (ARQT)? - simplywall.st ue, 21 Apr 2026 09
- Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback - Yahoo Finance Sun, 25 Jan 2026 08
- Insider Sale: Director at $ARQT Sells 10,000 Shares | ARQT Stock News - Quiver Quantitative ue, 06 Jan 2026 08
- Arcutis Biotherapeutics (ARQT) 2026 proxy details votes on board, pay and auditor - Stock Titan ue, 21 Apr 2026 20
- Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance Wed, 24 Dec 2025 08
- Planned sale: Arcutis (ARQT) director disposes of 10,000 shares - Stock Titan Fri, 03 Apr 2026 07
- Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results - simplywall.st Wed, 01 Apr 2026 07
- Assessing Arcutis Biotherapeutics (ARQT) Valuation After Its Strong 1-Year Share Price Surge - Yahoo Finance Wed, 03 Dec 2025 08
- Arcutis to give business update with Q1 results after market close May 6 - Stock Titan Wed, 15 Apr 2026 20
- Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy - Yahoo Finance hu, 25 Sep 2025 07
- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st ue, 09 Dec 2025 08
- Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - Stock Titan Wed, 01 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
376.07
+91.34%
|
196.54
+229.74%
|
59.61
+1517.09%
|
3.69
|
| Operating Revenue |
|
372.07
+123.41%
|
166.54
+470.62%
|
29.19
+691.81%
|
3.69
|
| Cost Of Revenue |
|
36.70
+91.84%
|
19.13
+283.56%
|
4.99
+561.41%
|
0.75
|
| Reconciled Cost Of Revenue |
|
36.70
+91.84%
|
19.13
+283.56%
|
4.99
+561.41%
|
0.75
|
| Gross Profit |
|
339.38
+91.29%
|
177.41
+224.82%
|
54.62
+1762.86%
|
2.93
|
| Operating Expense |
|
351.60
+14.97%
|
305.81
+3.41%
|
295.72
-2.90%
|
304.56
|
| Research And Development |
|
77.05
+0.83%
|
76.42
-30.89%
|
110.58
-39.39%
|
182.44
|
| Selling General And Administration |
|
274.55
+19.69%
|
229.39
+23.90%
|
185.15
+51.60%
|
122.12
|
| General And Administrative Expense |
|
—
|
—
|
—
|
—
|
| Other Gand A |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
388.30
+19.50%
|
324.94
+8.06%
|
300.71
-1.51%
|
305.31
|
| Operating Income |
|
-12.23
+90.48%
|
-128.40
+46.75%
|
-241.10
+20.07%
|
-301.63
|
| Total Operating Income As Reported |
|
-12.23
+90.48%
|
-128.40
+46.75%
|
-241.10
+20.07%
|
-301.63
|
| EBITDA |
|
1.78
+101.61%
|
-110.27
+51.76%
|
-228.56
+22.49%
|
-294.87
|
| Normalized EBITDA |
|
1.78
+101.61%
|
-110.27
+51.76%
|
-228.56
+22.49%
|
-294.87
|
| Reconciled Depreciation |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
-19.70%
|
0.93
|
| EBIT |
|
-2.89
+97.43%
|
-112.22
+51.06%
|
-229.31
+22.48%
|
-295.81
|
| Net Income |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Pretax Income |
|
-14.97
+89.26%
|
-139.39
+46.19%
|
-259.03
+16.83%
|
-311.46
|
| Net Non Operating Interest Income Expense |
|
-3.19
+71.15%
|
-11.04
+35.78%
|
-17.20
-9.86%
|
-15.65
|
| Interest Expense Non Operating |
|
12.08
-55.52%
|
27.17
-8.56%
|
29.71
+89.83%
|
15.65
|
| Net Interest Income |
|
-3.19
+71.15%
|
-11.04
+35.78%
|
-17.20
-9.86%
|
-15.65
|
| Interest Expense |
|
12.08
-55.52%
|
27.17
-8.56%
|
29.71
+89.83%
|
15.65
|
| Interest Income Non Operating |
|
8.90
-44.83%
|
16.13
+28.83%
|
12.52
|
—
|
| Interest Income |
|
8.90
-44.83%
|
16.13
+28.83%
|
12.52
|
—
|
| Other Income Expense |
|
0.44
+842.55%
|
0.05
+106.43%
|
-0.73
-112.56%
|
5.82
|
| Other Non Operating Income Expenses |
|
0.44
+842.55%
|
0.05
+106.43%
|
-0.73
-112.56%
|
5.82
|
| Tax Provision |
|
1.17
+80.99%
|
0.65
-79.22%
|
3.11
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income From Continuing Operation Net Minority Interest |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income From Continuing And Discontinued Operation |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income Continuous Operations |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Normalized Income |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Net Income Common Stockholders |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Diluted EPS |
|
-0.13
+88.79%
|
-1.16
+69.31%
|
-3.78
+33.22%
|
-5.66
|
| Basic EPS |
|
-0.13
+88.79%
|
-1.16
+69.31%
|
-3.78
+33.22%
|
-5.66
|
| Basic Average Shares |
|
127.23
+5.19%
|
120.96
+74.53%
|
69.31
+25.94%
|
55.03
|
| Diluted Average Shares |
|
127.23
+5.19%
|
120.96
+74.53%
|
69.31
+25.94%
|
55.03
|
| Diluted NI Availto Com Stockholders |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
432.97
+24.10%
|
348.89
+2.20%
|
341.37
-24.02%
|
449.27
|
| Current Assets |
|
411.23
+22.46%
|
335.82
+1.63%
|
330.43
-24.46%
|
437.41
|
| Cash Cash Equivalents And Short Term Investments |
|
220.98
-3.06%
|
227.96
-16.15%
|
271.86
-33.63%
|
409.59
|
| Cash And Cash Equivalents |
|
42.91
-39.85%
|
71.33
-19.30%
|
88.40
+64.80%
|
53.64
|
| Cash Equivalents |
|
42.91
-39.85%
|
71.33
-19.30%
|
88.40
+64.80%
|
53.64
|
| Other Short Term Investments |
|
178.07
+13.70%
|
156.62
-14.63%
|
183.46
-48.46%
|
355.95
|
| Receivables |
|
146.23
+100.13%
|
73.07
+183.12%
|
25.81
+205.12%
|
8.46
|
| Accounts Receivable |
|
146.23
+100.13%
|
73.07
+183.12%
|
25.81
+205.12%
|
8.46
|
| Taxes Receivable |
|
—
|
—
|
—
|
—
|
| Inventory |
|
22.63
+55.82%
|
14.53
+10.60%
|
13.13
+74.79%
|
7.51
|
| Raw Materials |
|
5.05
+17.37%
|
4.30
-56.79%
|
9.95
+75.84%
|
5.66
|
| Work In Process |
|
5.03
+761.82%
|
0.58
+20.16%
|
0.49
+23.04%
|
0.40
|
| Finished Goods |
|
12.55
+30.20%
|
9.64
+257.51%
|
2.70
+84.73%
|
1.46
|
| Prepaid Assets |
|
12.06
+13.65%
|
10.61
+1.11%
|
10.50
+141.07%
|
4.35
|
| Restricted Cash |
|
0.31
-50.08%
|
0.62
-33.30%
|
0.93
-25.04%
|
1.23
|
| Other Current Assets |
|
9.02
-0.29%
|
9.04
+10.17%
|
8.21
+31.18%
|
6.26
|
| Total Non Current Assets |
|
21.74
+66.36%
|
13.07
+19.53%
|
10.93
-7.87%
|
11.87
|
| Net PPE |
|
5.51
+84.03%
|
2.99
-23.23%
|
3.90
-15.25%
|
4.60
|
| Gross PPE |
|
8.76
+57.57%
|
5.56
-4.57%
|
5.82
+1.20%
|
5.75
|
| Accumulated Depreciation |
|
-3.25
-26.68%
|
-2.56
-33.26%
|
-1.92
-66.87%
|
-1.15
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
2.72
+33.68%
|
2.04
+7.49%
|
1.90
+29.26%
|
1.47
|
| Construction In Progress |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
4.47
+128.73%
|
1.95
-17.28%
|
2.36
-13.23%
|
2.72
|
| Leases |
|
1.57
+0.00%
|
1.57
+0.00%
|
1.57
+0.00%
|
1.57
|
| Goodwill And Other Intangible Assets |
|
14.81
+56.26%
|
9.48
+47.24%
|
6.44
-10.43%
|
7.19
|
| Other Non Current Assets |
|
1.42
+138.09%
|
0.60
+0.00%
|
0.60
+664.10%
|
0.08
|
| Total Liabilities Net Minority Interest |
|
243.49
+27.25%
|
191.35
-24.28%
|
252.70
+5.43%
|
239.69
|
| Current Liabilities |
|
129.84
+60.27%
|
81.01
+73.59%
|
46.67
+23.44%
|
37.81
|
| Payables And Accrued Expenses |
|
108.31
+79.71%
|
60.27
+94.02%
|
31.06
+34.17%
|
23.15
|
| Payables |
|
12.53
-11.90%
|
14.22
+18.58%
|
11.99
+35.86%
|
8.83
|
| Accounts Payable |
|
12.53
-11.90%
|
14.22
+18.58%
|
11.99
+35.86%
|
8.83
|
| Current Accrued Expenses |
|
95.78
+108.00%
|
46.05
+141.47%
|
19.07
+33.14%
|
14.32
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
20.53
-1.03%
|
20.75
+39.50%
|
14.87
+6.23%
|
14.00
|
| Current Debt And Capital Lease Obligation |
|
1.00
+21.95%
|
0.82
+11.56%
|
0.73
+11.87%
|
0.66
|
| Current Debt |
|
1.00
|
—
|
—
|
—
|
| Other Current Borrowings |
|
1.00
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
0.82
+11.56%
|
0.73
+11.87%
|
0.66
|
| Total Non Current Liabilities Net Minority Interest |
|
113.66
+3.01%
|
110.33
-46.45%
|
206.03
+2.05%
|
201.89
|
| Long Term Debt And Capital Lease Obligation |
|
113.22
+3.15%
|
109.77
-46.50%
|
205.18
+1.63%
|
201.89
|
| Long Term Debt |
|
107.96
+0.71%
|
107.20
-46.88%
|
201.80
+2.04%
|
197.77
|
| Long Term Capital Lease Obligation |
|
5.27
+105.54%
|
2.56
-24.25%
|
3.38
-17.85%
|
4.12
|
| Other Non Current Liabilities |
|
0.43
-24.39%
|
0.57
-32.86%
|
0.85
|
—
|
| Stockholders Equity |
|
189.48
+20.27%
|
157.54
+77.68%
|
88.67
-57.69%
|
209.58
|
| Common Stock Equity |
|
189.48
+20.27%
|
157.54
+77.68%
|
88.67
-57.69%
|
209.58
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+33.33%
|
0.01
+50.00%
|
0.01
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+33.33%
|
0.01
+50.00%
|
0.01
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
123.33
+4.65%
|
117.85
+21.76%
|
96.79
+58.57%
|
61.04
|
| Ordinary Shares Number |
|
123.33
+4.65%
|
117.85
+21.76%
|
96.79
+58.57%
|
61.04
|
| Additional Paid In Capital |
|
1,327.60
+3.76%
|
1,279.48
+19.52%
|
1,070.56
+15.06%
|
930.42
|
| Retained Earnings |
|
-1,138.08
-1.44%
|
-1,121.94
-14.26%
|
-981.90
-36.42%
|
-719.76
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.04
-528.57%
|
-0.01
-275.00%
|
0.00
+100.37%
|
-1.09
|
| Other Equity Adjustments |
|
-0.04
-528.57%
|
-0.01
-275.00%
|
0.00
+100.37%
|
-1.09
|
| Total Equity Gross Minority Interest |
|
189.48
+20.27%
|
157.54
+77.68%
|
88.67
-57.69%
|
209.58
|
| Total Capitalization |
|
297.44
+12.35%
|
264.74
-8.86%
|
290.47
-28.69%
|
407.35
|
| Working Capital |
|
281.39
+10.43%
|
254.81
-10.20%
|
283.76
-28.99%
|
399.60
|
| Invested Capital |
|
298.44
+12.73%
|
264.74
-8.86%
|
290.47
-28.69%
|
407.35
|
| Total Debt |
|
114.22
+4.06%
|
109.77
-46.69%
|
205.92
+1.67%
|
202.54
|
| Net Debt |
|
66.05
+84.15%
|
35.87
-68.37%
|
113.40
-21.32%
|
144.13
|
| Capital Lease Obligations |
|
5.27
+105.54%
|
2.56
-37.77%
|
4.12
-13.76%
|
4.77
|
| Net Tangible Assets |
|
174.67
+17.97%
|
148.06
+80.06%
|
82.23
-59.37%
|
202.39
|
| Tangible Book Value |
|
174.67
+17.97%
|
148.06
+80.06%
|
82.23
-59.37%
|
202.39
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.62
+94.98%
|
-112.16
+54.60%
|
-247.06
+4.14%
|
-257.71
|
| Cash Flow From Continuing Operating Activities |
|
-5.62
+94.98%
|
-112.16
+54.60%
|
-247.06
+4.14%
|
-257.71
|
| Net Income From Continuing Operations |
|
-16.14
+88.47%
|
-140.04
+46.58%
|
-262.14
+15.83%
|
-311.46
|
| Depreciation Amortization Depletion |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
-19.70%
|
0.93
|
| Depreciation |
|
—
|
0.64
-16.99%
|
0.77
+23.95%
|
0.62
|
| Amortization Cash Flow |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
+140.38%
|
0.31
|
| Depreciation And Amortization |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
-19.70%
|
0.93
|
| Amortization Of Intangibles |
|
4.67
+138.23%
|
1.96
+161.20%
|
0.75
+140.38%
|
0.31
|
| Other Non Cash Items |
|
2.41
-60.99%
|
6.17
+2.71%
|
6.01
-81.54%
|
32.55
|
| Stock Based Compensation |
|
40.36
-3.27%
|
41.73
+7.52%
|
38.81
+18.76%
|
32.68
|
| Operating Gains Losses |
|
—
|
-0.28
-132.86%
|
0.85
|
—
|
| Gain Loss On Investment Securities |
|
—
|
-0.28
-132.86%
|
0.85
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
-34.83
-130.96%
|
-15.08
+35.83%
|
-23.50
-130.97%
|
-10.18
|
| Change In Receivables |
|
-73.16
-54.81%
|
-47.26
-172.40%
|
-17.35
-105.12%
|
-8.46
|
| Changes In Account Receivables |
|
-73.16
-54.81%
|
-47.26
-172.40%
|
-17.35
-105.12%
|
-8.46
|
| Change In Inventory |
|
-7.33
-1732.25%
|
-0.40
+92.88%
|
-5.62
+25.21%
|
-7.51
|
| Change In Prepaid Assets |
|
-2.01
-111.71%
|
-0.95
+89.00%
|
-8.62
-348.30%
|
3.47
|
| Change In Payables And Accrued Expense |
|
48.35
+41.12%
|
34.26
+291.74%
|
8.75
+217.11%
|
2.76
|
| Change In Accrued Expense |
|
50.04
+56.23%
|
32.03
+472.63%
|
5.59
+368.90%
|
1.19
|
| Change In Payable |
|
-1.69
-176.00%
|
2.23
-29.28%
|
3.15
+101.41%
|
1.56
|
| Change In Account Payable |
|
-1.69
-176.00%
|
2.23
-29.28%
|
3.15
+101.41%
|
1.56
|
| Change In Other Current Liabilities |
|
-0.68
+7.48%
|
-0.73
-11.87%
|
-0.66
-51.73%
|
-0.43
|
| Investing Cash Flow |
|
-30.25
-204.97%
|
28.82
-84.01%
|
180.23
+306.69%
|
-87.20
|
| Cash Flow From Continuing Investing Activities |
|
-30.25
-204.97%
|
28.82
-84.01%
|
180.23
+306.69%
|
-87.20
|
| Net PPE Purchase And Sale |
|
-0.69
-379.72%
|
-0.14
+66.59%
|
-0.43
-28.53%
|
-0.33
|
| Purchase Of PPE |
|
-0.69
-379.72%
|
-0.14
+66.59%
|
-0.43
-28.53%
|
-0.33
|
| Capital Expenditure |
|
-10.69
-107.78%
|
-5.14
-1101.64%
|
-0.43
+98.16%
|
-23.28
|
| Net Investment Purchase And Sale |
|
-19.57
-157.61%
|
33.96
-81.20%
|
180.66
+382.65%
|
-63.92
|
| Purchase Of Investment |
|
-246.99
+3.07%
|
-254.82
-12.83%
|
-225.84
+45.63%
|
-415.39
|
| Sale Of Investment |
|
227.42
-21.25%
|
288.78
-28.96%
|
406.50
+15.66%
|
351.47
|
| Net Intangibles Purchase And Sale |
|
-10.00
-100.00%
|
-5.00
|
0.00
+100.00%
|
-22.95
|
| Purchase Of Intangibles |
|
-10.00
-100.00%
|
-5.00
|
0.00
+100.00%
|
-22.95
|
| Financing Cash Flow |
|
6.97
-89.47%
|
66.20
-34.66%
|
101.32
-66.43%
|
301.80
|
| Cash Flow From Continuing Financing Activities |
|
6.97
-89.47%
|
66.20
-34.66%
|
101.32
-66.43%
|
301.80
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-100.00
|
0.00
-100.00%
|
125.00
|
| Issuance Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
125.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-100.00
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
125.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-100.00
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-100.00
|
0.00
-100.00%
|
125.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
161.68
+63.48%
|
98.90
-43.82%
|
176.05
|
| Proceeds From Stock Option Exercised |
|
6.97
+54.27%
|
4.52
+86.62%
|
2.42
-17.56%
|
2.94
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-2.19
|
| Changes In Cash |
|
-28.91
-68.68%
|
-17.14
-149.67%
|
34.50
+180.01%
|
-43.12
|
| Effect Of Exchange Rate Changes |
|
0.17
+171.49%
|
-0.23
-370.00%
|
-0.05
|
0.00
|
| Beginning Cash Position |
|
71.95
-19.45%
|
89.32
+62.78%
|
54.88
-44.00%
|
97.99
|
| End Cash Position |
|
43.22
-39.94%
|
71.95
-19.45%
|
89.32
+62.78%
|
54.88
|
| Free Cash Flow |
|
-16.31
+86.09%
|
-117.30
+52.60%
|
-247.49
+11.93%
|
-281.00
|
| Interest Paid Supplemental Data |
|
10.33
-53.50%
|
22.21
-12.72%
|
25.45
+101.37%
|
12.64
|
| Amortization Of Securities |
|
-2.09
+69.66%
|
-6.90
+1.26%
|
-6.99
-210.21%
|
-2.25
|
| Common Stock Issuance |
|
0.00
-100.00%
|
161.68
+63.48%
|
98.90
-43.82%
|
176.05
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
161.68
+63.48%
|
98.90
-43.82%
|
176.05
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 10-K2026-02-25 View
- 8-K2026-02-25 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-07 View
- 42026-01-06 View
- 42026-01-02 View
- 42025-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|